Beijing All Life Medicine Technology

Beijing All Life Medicine Technology is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of innovative immune cell therapies for the treatment of solid tumors. The company utilizes its proprietary technology platforms to design and manufacture advanced CAR-T and TCR-T cell products that aim to enhance anti-tumor efficacy and persistence in the immunosuppressive tumor microenvironment. Its lead candidate, ALM-001, is a CAR-T therapy targeting Claudin 18.2, currently being evaluated in clinical trials for patients with advanced gastric and pancreatic cancers. All Life Medicine focuses on addressing the unmet medical needs of patients with refractory malignancies through cutting-edge genetic engineering and immunology research. The company's pipeline also includes programs targeting mesothelin and other undisclosed solid tumor antigens.